Merck’s backing of NGM Bio yields NASH drug deal

Merck & Co’s four-year R&D collaboration with NGM Biopharmaceuticals has borne its first fruit, a license deal for a drug with potential to treat non-alcoholic steatohepatitis (NASH) and type 2 diabetes. The mid-stage candidate, called NGM313, is http://www.pmlive.com/pharma_news/mercks_backing_of_ngm_bio_yields_nash_drug_deal_1273904